Looks like side effects are similar to Embrel. App
Post# of 72447
Posted On: 03/06/2016 8:10:20 AM
Looks like side effects are similar to Embrel. Appears to be an injection not oral like Prurisol.
The most common side effects for ixekizumab were colds and infections around the site of the injection, and in the trials comparing ixekizumab with Enbrel, the frequency and severity of side effects were similar for the two drugs, according to the release.
"The reviewers looked at the results from 3 trials: UNCOVER-1, UNCOVER-2, and UNCOVER-3. Each compared ixekizumab to a placebo, and UNCOVER-2 and UNCOVER-3 also compared it to etanercept. The reviewers considered week 12 the endpoint.
The reviewers describe UNCOVER-1 as being “a prospective, double-blind, multicenter trial that consisted of 1296 patients randomly distributed in a 1:1:1 ratio to receive 80 mg ixekizumab every two weeks (Q2W), 80 mg ixekizumab every 4 weeks (Q4W), or placebo.”
At week 12, patients receiving ixekizumab experienced a statistically significant improvement over those taking the placebo. The dosage regimens, according to the reviewers, “were similarly statistically superior to placebo.” However, the patients receiving ixekizumab also experienced more adverse events, most commonly nasopharyngitis and a reaction at the injection site.
UNCOVER-2 was “a prospective, double-blind, multicenter study that consisted of 1224 patients randomly distributed in 2:2:2:1 ratio to receive 80 mg ixekizumab Q2W, 80 mg ixekizumab Q4W, etanercept 50 mg twice weekly, or placebo,” according to the reviewers.
In this study, ixekizumab was superior to both etanercept and placebo. Again, though, the patients receiving ixekizumab experienced more adverse events than those taking placebo, however, the researchers add, “It is important to note that comparisons in adverse events are not statistically significant, as the studies are powered to detect differences in efficacy rather than rates of adverse events.” - See more at: http://www.hcplive.com/medical-news/psoriasis...GwndY.dpuf "
http://www.hcplive.com/medical-news/psoriasis...ixekizumab
The most common side effects for ixekizumab were colds and infections around the site of the injection, and in the trials comparing ixekizumab with Enbrel, the frequency and severity of side effects were similar for the two drugs, according to the release.
"The reviewers looked at the results from 3 trials: UNCOVER-1, UNCOVER-2, and UNCOVER-3. Each compared ixekizumab to a placebo, and UNCOVER-2 and UNCOVER-3 also compared it to etanercept. The reviewers considered week 12 the endpoint.
The reviewers describe UNCOVER-1 as being “a prospective, double-blind, multicenter trial that consisted of 1296 patients randomly distributed in a 1:1:1 ratio to receive 80 mg ixekizumab every two weeks (Q2W), 80 mg ixekizumab every 4 weeks (Q4W), or placebo.”
At week 12, patients receiving ixekizumab experienced a statistically significant improvement over those taking the placebo. The dosage regimens, according to the reviewers, “were similarly statistically superior to placebo.” However, the patients receiving ixekizumab also experienced more adverse events, most commonly nasopharyngitis and a reaction at the injection site.
UNCOVER-2 was “a prospective, double-blind, multicenter study that consisted of 1224 patients randomly distributed in 2:2:2:1 ratio to receive 80 mg ixekizumab Q2W, 80 mg ixekizumab Q4W, etanercept 50 mg twice weekly, or placebo,” according to the reviewers.
In this study, ixekizumab was superior to both etanercept and placebo. Again, though, the patients receiving ixekizumab experienced more adverse events than those taking placebo, however, the researchers add, “It is important to note that comparisons in adverse events are not statistically significant, as the studies are powered to detect differences in efficacy rather than rates of adverse events.” - See more at: http://www.hcplive.com/medical-news/psoriasis...GwndY.dpuf "
http://www.hcplive.com/medical-news/psoriasis...ixekizumab
(0)
(0)